UNICREDIT BANK/CALL/BIOGEN IDEC/350/0.1/19.03.25 | Market Closed - Börse Stuttgart 19:41:47 17/05/2024 BST | ||
| 0.55 EUR | +17.02% |
|
| Current month | +103.70% | ||
| 1 month | +205.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.55 | +17.02% |
| 16/05/24 | 0.47 | -16.07% |
| 15/05/24 | 0.56 | +33.33% |
| 14/05/24 | 0.42 | +5.00% |
| 13/05/24 | 0.4 | +8.11% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 07:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD43Q8 |
| ISIN | DE000HD43Q82 |
| Date issued | 25/03/2024 |
| Strike | 350 $ |
| Maturity | 19/03/2025 (306 Days) |
| Parity | 10 : 1 |
| Emission price | 0.63 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.59 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.02 € |
| Spread % | 3.39% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Warrants
- Warrant
